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Abstract
There has long been a recognised association between non-alcoholic fatty liver
disease (NAFLD) and the composite aspects of the metabolic syndrome. Part of
this association highlighted the supposed co-existence of elevated uric acid levels
in those with NAFLD. There is interest in exploitation of this as a putative
diagnostic and prognostic biomarker in NAFLD. Given the increased economic
and health burden associated with the NAFLD epidemic, improved methods of
population-based, minimally-invasive methods and biomarkers are clearly highly
sought and necessary. In this opinion review we review the proposed role of uric
acid in the pathogenesis of NAFLD and its potential utilisation in the diagnosis
and monitoring of the disease process.
Key words: Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Uric acid;
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Core tip: There is significant interest in the role of uric acid as both a causative
aetiological proponent in non-alcoholic fatty liver disease as well as its diagnostic utility
in the diagnosis of fatty liver disease. Within this review we explore these putative
molecular mechanisms which are likely implicated, in addition to exploring the most
recent translational evidence of uric acid as a diagnostic tool in the clinical environ.
Citation: Brennan P, Clare K, George J, Dillon JF. Determining the role for uric acid in non-
alcoholic steatohepatitis development and the utility of urate metabolites in diagnosis: An
WJG https://www.wjgnet.com April 21, 2020 Volume 26 Issue 151683
Article in press: April 8, 2020
Published online: April 21, 2020
P-Reviewer: Abenavoli L, Han T,
Pellicano R, Tiribelli C, Xu CF
S-Editor: Wang YQ
L-Editor: A
E-Editor: Ma YJ
opinion review. World J Gastroenterol 2020; 26(15): 1683-1690
URL: https://www.wjgnet.com/1007-9327/full/v26/i15/1683.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i15.1683
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of disease ranging
from simple fatty liver (steatosis; NAFL) to fatty liver with cell inflammation and
ballooning  (non-alcoholic  steatohepatitis;  NASH).  Within  this  continuum is  the
propensity for progression to cirrhosis with its associated sequelae of end-stage liver
failure and hepatocellular carcinoma. NASH; in particular with advanced fibrosis,
represents a significant unmet medical need, with limited non-invasive screening and
diagnostic and monitoring tools. The defining characteristic of NAFLD is a more than
5% lipid deposition within the liver in the absence of excess alcohol consumption,
defined as > 20 g/d for women and 30 g/d for men[1].
The development of NAFLD is strongly linked to insulin resistance, diabetes and
obesity. This relationship is well established and NAFLD is widely considered to be a
hepatic  manifestation  of  the  metabolic  syndrome[2].  There  are  however,  clearly
additional implicated factors which are as yet not completely determined. NAFLD
development and progression is likely multifactorial and involve an interplay of
genetic, environmental, metabolic and gut microbial factors[3]. The exact mechanisms
which underlie the pathogenesis of NAFLD are not yet fully understood. Multiple
research programmes are evolving towards uncovering the relevant pathological
mechanisms, thereby identifying therapeutic targets in NAFLD as there is a clear
unmet clinical need for pharmacotherapy in its management.
A number of studies have shown an association between elevated serum uric acid
(UA) levels and the development of NAFLD[4,5]. One paper reports a prevalence of
hyperuricemia of 78% in NAFLD subjects and 41% in non-NAFLD with a study group
of 147 and 832 respectively[6]. The association appears to be stronger in females[7] and
dose-dependent[8]. UA is the final oxidation product of purine metabolism in humans.
It is a relatively insoluble waste by-product which can accumulate in the serum if
there is an imbalance in its formation or excretion[9]. The majority of purines are made
endogenously whilst a smaller proportion come from a dietary source. Given there is
a  dietary  link,  there  is  increasing  evidence  to  support  the  promotion  of  the
Mediterranean diet for the prevention and treatment of NAFLD[10].
Hyperuricemia  is  well  known  to  co-exist  with  other  “metabolic”  conditions
including insulin resistance, obesity, hypertension and atherosclerosis. More recently,
studies  have shown that  having elevated levels  of  serum UA is  an independent
predictor of NAFLD[11]. It is not established however, whether these high levels are
causative or represent the effect of the metabolic syndrome.
Some of the putative mechanisms for NAFLD development relating to UA are
summarised in Figure 1.
PROPOSED ROLE OF UA IN THE PATHOGENESIS OF
NAFLD
The role of urate and xanthine oxidase in NAFLD
Previously, it has been demonstrated that urate exerts an intracellular pro-oxidant
and pro-inflammatory effect  in adipose tissue[9,12,13].  Whilst  there are studies that
suggest that a rise in urate might be an anti-oxidant response to increased oxidative
stress and adiposity,  current evidence suggests  that  in NAFLD, it  functions as a
marker of xanthine oxidase (XO) activity[14].  To further substantiate this evidence,
recent studies have shown a significantly raised XO levels in patients with NAFLD
compared to controls[15].  A recent study in 5541 individuals showed that NAFLD
significantly increased the risk of incident hyperuricemia and demonstrated in mouse
models  of  NAFLD  that  XO  mediates  the  relationship  between  NAFLD  and
hyperuricemia. The authors therefore suggested that XO inhibition may serve as a
novel therapeutic target for NAFLD[4]. Urate has also been shown to increase fatty
accumulation  in  the  liver  by  increasing  endoplasmic  reticulum  (ER)  stress  via
transcriptional factors including sterol regulatory element-binding protein-1 (SREBP-
1c) activation in hepatocytes[16].
It is unsurprising that XO may play an important role in NAFLD as XO is widely
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Figure 1
Figure 1  Potential pathogenic mechanisms of uric acid associated non-alcoholic fatty liver disease. NLRP3:
NOD-like receptor family pyrin domain containing 3; ER: Endoplasmic reticulum; SREBP-1: Sterol regulatory element-
binding protein 1; NOX4: NADPH oxidase subunit-4; ROS: Reactive oxygen species.
distributed throughout various organs including the liver, gut, lung, kidney, heart,
brain and plasma[17] with the highest levels being found in the gut and the liver[18]. A
fully reduced XO contains six electrons and its re-oxidation involves electron transfer
to  oxygen molecules  which generates  two molecules  each of  the  potent  reactive
oxygen species, hydrogen peroxide (H2O2) and superoxide anion (O2-) species[19] for
every fully reduced XO molecule, thereby generating significant oxidative stress each
time a molecule of urate is formed. Superoxide anions then react with water and nitric
oxide to generate further free radicals such as hydroxyl and peroxynitrite radicals.
There is evidence to support both the direct and indirect effects of UA in NAFLD
pathogenesis  and  progression.  Previously,  high  levels  of  serum  UA  had  been
regarded as beneficial, due to its ability to act as an antioxidant. However, once UA
becomes intracellular it loses its favourable anti-oxidative properties and its action
paradoxically; appears to be detrimental[20].
UA and NADPH oxidase subunit-4
With regards  to  its  direct  effects,  studies  have shown that  UA can stimulate  fat
synthesis  within  hepatocytes[16].  UA  promotes  the  translocation  of  the  NADPH
oxidase  subunit-4  (NOX4)  into  the  mitochondria  which  increases  superoxide
generation. This increase in reactive oxygen species inhibits aconitase, an enzyme
which catalyses the isomerisation of citrate to iso-citrate in the mitochondrial matrix
during the TCA cycle. The inhibition of aconitase leads to accumulation of citrate in
the mitochondria. When this citrate is released into the cytosol, it activates the ATP
sensitive enzyme ATP-citrate lyase through phosphorylation at SER455. This converts
citrate to acetyl-CoA for de novo lipogenesis through fatty acid synthase[20].
These observations have been supported by work which has shown that a UA
driven increase in mitochondrial oxidants could be prevented with pre-administration
of apocynin, an antioxidant and NOX inhibitor or by silencing NOX4[20].Consistent
with these proposed mechanisms the study has also shown in hepatocytes exposed to
UA,  there  was  a  77.4%  reduction  aconitase  activity  as  well  as  a  substantial
accumulation of citrate in the cytosol of hepatocytes when cells are exposed to UA[20].
UA and ER stress
Research in both HepG2 cells and primary mouse hepatocytes has also described
additional  mechanisms  in  which  UA  contributes  to  lipid  accumulation  in
hepatocytes[16]. Reactive oxygen species produced by UA and cellular membrane NOX
prompts a cascade of ER stress and release of lipogenic transcription factor SREBP-
1c[16].
The ER has a key role in cellular function, responsible for the folding of proteins
and synthesis of lipids. It is therefore highly sensitive to homeostatic changes and
when under stress, misfolded and unfolded proteins accumulate and activate the
unfolded protein response (UPR) signalling pathways in an attempt to counteract
potentially harmful changes. Studies have shown that UPR regulate the expression of
lipogenic enzymes through inositol-requiring enzyme 1, an ER stress sensor, and xbox
binding protein 1 a transcription factor important in the cellular stress response[21].
Recent data has shown that UPR signalling and ER stress is involved in the regulation
of hepatic lipid metabolism and NAFLD development[22].
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The  transcription  factor  SREBP-1  regulates  the  gene  expression  of  lipogenic
enzymes. Studies in both HepG2 cells and primary mouse hepatocytes show that UA
can  increase  the  cleavage  of  SREBP-1  into  its  mature  form  and  cause  nuclear
translocation. Choi et al[16]  have shown an upregulation of SREBP-1 and lipogenic
enzymes in these cell models when exposed to UA which subsequently promotes de
novo lipogenesis.
From this research it is fairly clear that in hepatocytes exposed to UA there is a
pathogenic overlap between oxidative and ER stress.  Both mechanisms cause an
increase in expression of lipogenic genes and hepatocellular lipogenesis.
UA and inflammasome activation
Previous research has reported that UA can activate the NOD-like receptor family
pyrin  domain  containing  3  (NLRP3)  inflammasome[23].  This  is  an  intracellular
multiprotein  complex  which  has  the  ability  to  identify  pathogenic  or  harmful
molecular signals[8] Activation of NLRP3 has been shown to stimulate caspase-1 to
cleave pro-interleukin (IL)-1b and pro-IL-18 into mature forms which causes their
release from the cell. Although the specific pathogenic mechanisms underlying UA
activation of the NLRP3 inflammasome and related hepatic steatosis are unknown, it
is clear from the studies in both mice hepatocytes and cultured cell lines there is an
association[24].
Research in mice fed a ‘hyperuricemia-inducing’ diet for eight weeks showed there
was a significant increase in hepatic mRNA expression of NLPR3, caspase-1, IL-1b
and IL-18. The same mice models had elevated levels of serum IL-1b and IL-18 as well
as increased protein expression of IL-1b, IL-18, caspase-1 and NLPR3. Studies have
also revealed elevated levels of NLRP3 expression and its components in humans
with NASH[25].
To investigate the role of NLRP3 in UA induced steatohepatitis, the same research
group  knocked  out  NLRP3  in  HepG2  cells[24].  They  found  that  deletion  of  this
inflammasome significantly reduced UA related lipogenesis  in this  cell  line and
improved insulin signalling. The researchers therefore suggest that NLRP3 has a role
in impaired insulin signalling related to UA[24]. A cautionary note however, NLRP3
signalling  is  complex  and  involves  a  number  of  direct  and  indirect  canonical
pathways with multiple other known stimulatory molecules.
EVIDENCE FOR URATE METABOLITES IN INDIVIDUALS
WITH NAFLD AND IS THERE DIAGNOSTIC POTENTIAL IN
SERUM UA MEASUREMENT
Evidence in NAFLD
Given  a  paucity  of  reliable  biomarkers  in  the  diagnosis  and  prognostication  of
NAFLD, there has been an increasing interest in UA as a diagnostic utility.
As has been alluded to previously, there is increased evidence of the association of
UA as an independent determinant of NAFLD, with some studies demonstrating an
association even in lean/non-obese cohorts[26-28]. What is less clear is the utility of urate
and its  constituent  degradation  products  in  the  diagnosis  or  prognostication  of
NAFLD. There would be particular attraction in incorporation of such a metabolite in
to the various existing non-invasive fibrosis algorithms, particularly if it improved
specificity of diagnosis.
Recently,  a  prospective population study in Montenegro sought to establish a
diagnostic cut-off value of UA which may predict NAFLD[29]. The authors used the
Fatty liver index (FLI) as a proxy reference standard for NAFLD diagnosis, with a
score of > 60 established as the cut off. A total of 771 patients from the initial 1,000
screened where deemed suitable for the study. Interestingly, within this populace it
was found that ALT was an independent predictor of FLI in both women and men.
Contrastingly, SUA was only independently predictive of FLI in women but not in
men.
Jensen et al[30] demonstrated in a Japanese cohort that serum UA (SUA) which was
elevated at baseline, and those with an incrementing SUA over 5 years were both
independent risk factors for developing NAFLD. This finding was substantiated in
both normal and borderline liver cohorts, including those young individuals and
those with increased body mass index (BMI).  Whilst  the study had a number of
powerful aspects, it is limited by a number of elements including that of being an
observational cohort and using an unselected cohort with limited adjustment for
concomitant  background  populace  disease.  The  authors  urged  caution  in
interpretation of the findings, since the study was again not designed to determine
causality.
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A comprehensive, liver-biopsy defined study in Egypt sought to develop a new
non-invasive  scoring  modality  for  both  NAFLD  histological  severity  and
cardiovascular  morbidity[31],  which  examined a  wide  assortment  of  biochemical
markers including SUA. The study ultimately included 61 patients across two centres
with NAFLD and metabolic features. They excluded those with hepatotropic viruses,
use of confounding medications, excessive alcohol consumption or patients taking
insulin. The outcomes demonstrated that SUA did not offer improved diagnostic
accuracy with significant fibrosis in NAFLD predicted by nine alternative parameters.
Finally, there is an encouraging study published by Culafic et al[32] whereby they
proposed a model to predict NASH from simple steatosis in a NAFLD cohort. The
HUFA-model  incorporates;  HOMA-IR,  UA,  Ferritin  and  ALT.  Patients  were
subdivided into two cohorts:  Those with simple steatosis and NASH. In total,  82
patients  had  simple  steatosis  (33  with  a  representative  liver  biopsy)  and  29
individuals demonstrated biopsy-proven NASH. There was a significant difference in
the SUA between those with simple steatosis and those with biopsy confirmed NASH
(SUA  346.2  ±  84.7  µmol/L  vs  423.5  ±  83.1  µmol/L,  P  =  0.001).  Further  analysis
demonstrated that SUA levels correlated with inflammation on a histological basis.
Overall,  the  model  demonstrated  that  in  combining  all  of  the  representative
components, an area under the ROC curve of 0.94 was achieved. This corresponded to
a sensitivity and sensitivity of 70.3% and 95.1% respectively for NASH. Similarly, this
meant positive and negative predictive values of 83.1% and 90%.
Lean-NAFLD
While there are obviously parallels between elevated levels of SUA in patients with
features  of  the  metabolic  syndrome;  there  is  now  significant  interest  in  “lean-
NAFLD”.  This  is  traditionally  defined  as  BMI  <  25;  with  variable  geographical
prevalence. In the United States; studies have suggested a prevalence of 7%-9%[33,34],
this is in contrast to reported prevalence rates in Hong-Kong, China (19.3%)[35] and
other Asian-Pacific  countries and regions with incidence purportedly of 5%-30%
depending on the populations studied[36].
A large study by Zheng et al[28] and colleagues analysed 95924 patients from routine
clinic  appointments  in  Chongqing,  China.  The  found  lean-NAFLD  in  7503
participants (8.16%), with 6967 having mild steatosis and 536 with moderate to severe
disease. Those patients normal BMI with hyperuricaemia demonstrated an increased
preponderance  to  NAFLD (OR =  1.718;  95%CI:  1.622-1.820)  upon correction  for
confounding metabolic sequelae.  The area under curve for identification of mild
steatosis based on SUA was 0.70; whilst its utility in the detection of moderate and
severe fatty liver was 0.78.
In a separate Chinese cohort[37], 9293 individuals undergoing routine health screens
were assessed for evidence of lean-NAFLD using BMI < 24 kg/m2 as the threshold.
Seven hundred and forty of those screened had sonographic and laboratory indices in
keeping  with  NAFLD,  thus  giving  an  incidence  of  18.5%.  Again,  SUA  was
independently associated with NAFLD. Across multiple applied regression analysis,
SUA was a reproducible risk factor with a univariate OR = 1.435 (P < 0.001). The area
under  curve  of  SUA  was  0.64  (95%CI:  0.63-0.66;  P  <  0.001),  with  the  authors
suggesting within their cohort that UA > 6 mg/dL had a useful discriminant value.
Despite  the  large  numbers  of  patients  within  these  studies  there  are  inherent
aspects that may attribute relative bias. This includes accuracy of alcohol estimates
and recall biases of individuals and alcohol-related fatty liver is the most common
mimic  of  NAFLD.  Certainly,  Chinese  patients  have  a  lower  BMI  than  western
counterparts, however, there may be surreptitious metabolic determinants at play,
which are not entirely appreciated in the lean populace[38].
Within  the  Zheng  et  al[28]  cohort,  as  a  retrospective  study  is  limited  in  only
specifically excluding those individuals who had known alternative chronic liver
disease, but did not account for those who had potentially undiagnosed hepatotropic
viruses or lipid disorders.
Whilst  there  is  some  incipient  evidence  in  animal  models  relating  to  NASH
amelioration in response to UA lowering intervention[14,24,39,40], to date; there are no
direct clinical trials establishing these outcomes in humans on NAFLD progression or
mortality, and the only recommended intervention is that of 7-10% weight loss as per
European Association for the Study of the Liver guidelines[41].
CONCLUSION
Whilst  the  evidence  reviewed  herein  demonstrates  undeniable  co-existence  of
increased SUA across a continuum of NAFLD cohorts,  the evidence for causality
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remains tenuous. As with a number of NAFLD studies, there is a predominance of
observational and retrospective works within the literature, which suffer inherent
biases. There is significant heterogeneity in the standards used for exacting NAFLD
across such works including use of non-invasive modalities, all of which have relative
limitations. This however, is reflective of the challenges faced in real world clinical
practice,  accurately mirroring the diverse NAFLD continuum and the diagnostic
conundrum it poses. This is clearly illustrated by the divergent prevalence of “lean-
NAFLD” and its  geographical  predilections and presents  a  further  confounding
entity.
Unfortunately, there is clearly no absolute evidence for incorporating UA in the
diagnostic algorithms as they presently exist for large undifferentiated populous
screening. Feasibly, large datasets which incorporate specific advanced diagnostic
components  including  Enhanced  Liver  Fibrosis  test  or  the  algorithmic-based
intelligent Liver Function Test[42] system may have a place for inclusion of UA in their
respective methods.
UA is an attractive biomarker from a number of perspectives including cost basis
and almost universal access to reproducible assays. There is perhaps some distinct
subtleties’ emerging around the use of UA in defined subgroups, including that of the
lean-NAFLD cohorts  and in distinguishing mild or simple steatosis  from that  of
moderate to severe variants.
Undoubtedly, efforts to maximise any potential role for UA should be pursued
given  the  enormous  challenges  that  lie  ahead  in  NAFLD  diagnosis  and
prognostication.
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